Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

This study has been completed.

First Received: September 14, 2006 Last Updated: September 23, 2008 History of Changes

Sponsor:	Innovative Medical
Information provided by:	Innovative Medical
ClinicalTrials.gov Identifier:	NCT00377546

Purpose

To compare the penetration of three different NSAIDs.

Condition	Intervention	Phase
Vitrectomy	Drug: Nepafenac Drug: Ketorolac LS, Bromfenac	Phase IV

Study Type:	Interventional
Study Design:	Randomized, Double-Blind, Active Control, Parallel Assignment

Resource links provided by NLM:

Drug Information available for: Ketorolac Ketorolac tromethamine Nepafenac Bromfenac Bromfenac sodium

U.S. FDA Resources

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Males or females scheduled to undergo Vitrectomy surgery
Likely to complete all study visits and able to provide informed consent
Visual potential of 20/25 or better

Exclusion Criteria:

Known contraindications to any study medication or ingredients
Active ocular diseases or uncontrolled systemic disease
Active ocular allergies

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00377546

Locations

United States, Massachusetts
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States, 02114

Sponsors and Collaborators

Innovative Medical

Investigators

Principal Investigator:

Jeffrey Heier, MD

Ophthalmic Consultants of Boston

More Information

No publications provided

Study ID Numbers:	5264
Study First Received:	September 14, 2006
Last Updated:	September 23, 2008
ClinicalTrials.gov Identifier:	NCT00377546 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Innovative Medical:

Retinal Surgery

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Bromfenac
Sensory System Agents
Analgesics, Non-Narcotic
Therapeutic Uses
Physiological Effects of Drugs

Anti-Inflammatory Agents, Non-Steroidal
Peripheral Nervous System Agents
Analgesics
Antirheumatic Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010